Русский / English
Enter the query
Petrovax Pharm
16,9 mln
doses of flu vaccine supplied to Russia’s regions


NPO Petrovax Pharm brings its research developments to full-scale manufacturing in its state-of-the-art high-tech biopharmaceutical plants. The company’s manufacturing is in full compliance with the GMP EU and ISO:9001 international standards.

The company’s product porfolio includes only innovative medicines and vaccines sold within Russia as well as CIS and EU countries.

The company’s principal areas of focus are the production of flu vaccine for the national immunization calendar and the development and production of immunobiologicals and long-acting nanobio drugs.

The staff of Petrovax Pharm includes more than 600 highly skilled employees. The company has its own research subdivision headed by prominent Russian scientists.

Petrovax Pharm has been a member of the Association of Russian Pharmaceutical Manufacturers (ARPM) since 2008.

NPO Petrovax Pharm’s key objective is to manufacture innovative medicines and vaccines developed based on fundamental research.
As of today the companies holds more than 20 world patents for molecules, inventions, and manufacturing technologies.
  • Driven by the vital needs of the healthcare system, the product portfolio contains only original medicines, including:
  • Polyoxidonium – an effective drug with a combination of properties: immunomodulator, detoxifier, and antioxidant;
  • Longidaze – a multifunctional enzymatic drug to treat diseases that involve connective tissue hyperplasia;
  • the Grippol® and Grippol® Plus group of flu vaccines, the main flu vaccines in Russia, with a 90% market share. The government of Russia procures the vaccines under the national immunization calendar for use primarily in children older than 6 months, the elderly and chronically ill patients, as well as all other population groups.
  • Prevenar® 13, a 13-valent pneumococcal conjugated vaccine.
Petrovax Pharm does not rest on its laurels. It continues to research, develop, and commercialize new products.
  • Vitaoximer® is an innovative detoxifier, able to effectively fight acute and chronic intoxications of different etiologies
  • Three extended-release recombinant protein-based nanobio preparations will be launched soon
  • Hyaluronidase enzyme-based cosmetic treatment to remove skin scarring is currently under development. 

NPO Petrovax Pharm is one of the most modern high technology pharmaceutical manufacturing companies in Russia, producing active ingredients and medicines in various pharmaceutical forms in full compliance with the EU GMP and ISO:9001 international standards.

Today the company’s plans are mainly related to operations in the pharmaceutical manufacturing and warehousing facilities that were put on line in September 2008 in the town of Pokrov, Podolsk Region, Moscow Oblast. The Serbian company OPART designed and built the plant in full compliance with European GMP requirements. The plant’s first line produced prefilled syringes and Grippol Plus vaccine. In 2009 Polyoxidonium and Longidaze production came on line, with a capacity of 80 million vials and ampoules per year, as did production of infusion solutions in polymer containers. Construction of lines three and four, to manufacture active ingredients and solid and semi-solid dosage forms began three years later. Manufacturing expansion plans include construction of a 5th manufacturing line, construction of an administrative building, and warehouse expansion. 

The NPO Petrovax Pharm quality control system has passed numerous audits by recognized leaders in the global pharmaceutical industry, including Pfizer and Abbott. Since its founding, Petrovax Pharm has passed more than fifteen inspections by Russian and foreign commissions that endorsed the quality control system at the plant as being compliant with GMP requirements.

In 2012 Petrovax Pharm obtained EU GMP manufacturing and quality management system (QMS) compliance certificates from the appropriate agencies of Ukraine and Slovakia. 

NPO Petrovax Pharm employs more than 600 highly skilled professionals able to resolve even the thorniest issues that arise when new technologies are being implemented.

The company offers solid opportunities for professional and personal growth through an integrated training system for different employee groups. Those employed in manufacturing have regular trainings on the GMP EU standards. In addition, the company pays for continuing education courses in centers for professional advancement. Some employees have been sent for internships in companies outside of Russia. 

Petrovax Pharm’s collaboration with the world’s leading pharmaceutical companies opens up new potential export opportunities. This is tremendously important for Petrovax Pharm, a company that has always considered geographic market expansion one of its strategic priorities.

The company’s market expansion efforts have brought impressive results. Today Petrovax Pharm exports its products to the following EU and CIS countries: Ukraine, Belarus, Kazakhstan, Kyrgyz Republic, Azerbaijan, Uzbekistan, Georgia, Moldova, and Slovakia.  

High manufacturing and research standards, focus on innovation, and highly skilled employees made Petrovax Pharm an attractive partner for the world’s leading pharmaceutical companies. Today it successfully works with Pfizer and Abbott, partner companies that have transferred technologies, shared their knowledge of the intricacies of the manufacturing process, and provided significant support for the company’s further development.

Upon the completion of the key stage of the project in 2012, NPO Petrovax Pharm became a local producer of Prevenar® 13, a pneumococcal 13-valent vaccine. Pfizer and-NPO Petrovax Pharm’s joint vaccine localization project won the Russian Platinum Ounce competition in the Project of the Year category. 

Press Center
The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
The event took place within the framework of the educational project «We and Media». Participants of the round table discussed ways of fighting dangerous infectious diseases and the role of the media in the popularization of the vaccine prophylaxis.
At a conference on communication in the pharmaceutical industry, delegates discussed issues relevant to the pharmaceutical industry and emphasized the importance of open conversation and ongoing dialogue between the media and market experts.
NPO Petrovax Pharm passed an audit by the State Institute of Pharmaceuticals Quality Control of Slovakia, and was once again awarded the EU GMP production and quality management compliance certificate.
Interros Group is acquiring a controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.  The parties signed the documents in Moscow today. Arkady Nekrasov and Natalia Puchkova, NPO Petrovax Pharm founders, will retain a stake in the company, and will continue to participate in business management. Financial terms of the deal are not disclosed.